↓ Skip to main content

Dove Medical Press

Article Metrics

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
reddit
1 Redditor

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
6 Mendeley
Title
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Published in
Therapeutics and Clinical Risk Management, July 2017
DOI 10.2147/tcrm.s140023
Pubmed ID
Authors

Salma Al Dallal

Abstract

Ofatumumab Arzerra(®) is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody's therapeutic effect on chronic lymphocytic leukemia.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 50%
Student > Bachelor 1 17%
Student > Ph. D. Student 1 17%
Other 1 17%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 2 33%
Medicine and Dentistry 2 33%
Immunology and Microbiology 1 17%
Agricultural and Biological Sciences 1 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2017.
All research outputs
#8,184,367
of 13,566,763 outputs
Outputs from Therapeutics and Clinical Risk Management
#564
of 970 outputs
Outputs of similar age
#144,221
of 266,532 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#10
of 17 outputs
Altmetric has tracked 13,566,763 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 970 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,532 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.